Sort
48,018 grants matching “immunotherapy”
Identification of radiosensitizers for prostate cancer
$1,001,043Travis Stracker · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer
$1,001,029Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2024 · CA
Cancer and Leukemia Group B-Leukemia Correlative Science
$1,000,836Michael A Caligiuri · Ohio State University · U10 · FY2008 · CA
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy
$1,000,669Irving Lerner Weissman · Stanford University · R35 · FY2023 · CA
Developmental Funds
$1,000,554Candace S Johnson · Roswell Park Cancer Institute Corp · P30 · FY2020 · CA
Developmental Funds
$1,000,554Candace S Johnson · Roswell Park Cancer Institute Corp · P30 · FY2021 · CA
Developmental Funds
$1,000,554Candace S Johnson · Roswell Park Cancer Institute Corp · P30 · FY2019 · CA
Development of novel immunotherapy for influenza virus infection
$1,000,001Kazue Takahashi · Massachusetts General Hospital · U01 · FY2007 · AI
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
$1,000,001Robert A Wood · Johns Hopkins University · UM2 · FY2021 · AI
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2020 · CA
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
$1,000,000M. Javad Aman · Abvacc, Inc. · R44 · FY2025 · AI
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
$1,000,000Robert A Wood · Johns Hopkins University · UM2 · FY2020 · AI
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
$1,000,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2020 · CA
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
$1,000,000Michael Chiu · Kytopen Corp · R44 · FY2025 · AI
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
$1,000,000Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2019 · AI
Immunotherapy of MRSA Osteomyelitis
$1,000,000M. Javad Aman · Abvacc, Inc. · R44 · FY2023 · AI
Therapy and Prophylaxis for Genital Tract Infection
$1,000,000Dominick Auci · Therapyx, Inc. · SB1 · FY2025 · AI
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2013 · AI
Programming Metabolically Fit TILs for Immunotherapy
$1,000,000Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R42 · FY2024 · CA
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2014 · AI
Therapy and Prophylaxis for Genital Tract Infection
$1,000,000Dominick Auci · Therapyx, Inc. · SB1 · FY2024 · AI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2022 · CA
Development of a novel accurate therapy for multiple sclerosis
$1,000,000Gaddiel Galarza-Munoz · Autoimmunity Biologic Solutions, Inc. · R42 · FY2022 · AI